Literature DB >> 6184574

Experience with nitrendipine--a new calcium antagonist--in hypertension.

L Andrén, L Hansson, L Orö, T Ryman.   

Abstract

The antihypertensive effect of 20 mg of nitrendipine (BAY e 5009) was compared with that of 40 mg, administered orally once daily to 12 patients with essential hypertension (WHO I-II). The study was designed as a double-blind, within-patient comparison. The present results indicate that nitrendipine has a significant antihypertensive effect both at 20 and 40 mg as compared to placebo. There was no significant change in heart rate with 20 mg of nitrendipine, whereas there was a significant increase in heart rate after the first dose of 40 mg. Nitrendipine in dosages of 20 mg and 40 mg daily was equally effective as regards the antihypertensive effect. This applies both to the early response (first day) and the late response (3 weeks). Side effects were common in the 40-mg treatment group, but rare in the 20-mg group; only one patient had headache (three times) during the 3-week treatment period. It can be concluded that in mild hypertension, treatment with 20 mg of nitrendipine once daily constitutes an effective antihypertensive therapy. In more severe cases of hypertension, however, combination treatment with beta-blockers, for example, and/or repeated daily administration of nitrendipine ought to be investigated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184574     DOI: 10.1097/00005344-198200433-00025

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

2.  The natriuresis following oral administration of the calcium antagonists--nifedipine and nitrendipine.

Authors:  M D Ene; P J Williamson; C J Roberts; G Waddell
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

3.  Treatment of essential hypertension with felodipine in combination with a diuretic.

Authors:  T Hedner; O Samuelsson; E Sjögren; D Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Nitrendipine therapy in asthmatic subjects.

Authors:  E M Mulloy; P Cormie; J Harvey; J E Marley
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

5.  Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.

Authors:  J R M'Buyamba-Kabangu; B Lepira; R Fagard; P Lijnen; M Ditu; K A Tshiani; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy.

Authors:  M R Lawrence; F Broughton Pipkin
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 7.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

8.  Calcium-channel blockers and sodium intake: a controlled study in patients with essential hypertension.

Authors:  F Galletti; P Strazzullo; F P Cappuccio; G Barba; N Giorgione; R Gagliardi; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.